Imprimis Pharmaceuticals is a publicly traded pharmaceutical company (NASDAQ: IMMY) based in San Diego. It makes eye drops, compounded medicines and other products.
It manufactures a pyrimethamine and leucovorin compound which may offer a low-cost "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000% by Martin Shkreli and Turing Pharmaceuticals.
In 2016, the company was ranked #12 on the Deloitte Fast 500 North America list.
In October 2015, Anthony Principi was elected to the company's board of directors.